A-Alpha Bio

A-Alpha Bio is a seed-stage drug discovery company that leverages synthetic biology and next generation sequencing tools to measure protein-protein interactions in high-throughput. The company has developed a platform called AlphaSeq that uses genetically engineered yeast cells to quantitatively characterize millions of protein-protein interactions simultaneously at a library-on-library scale - generating enormous amounts of data that informs the discovery of effective and highly specific biologic and small-molecule drugs. A-Alpha Bio partners with pharmaceutical companies to discover and optimize high-impact therapeutics.